FullCircle Wealth’s Biogen BIIB Stock Holding History

FullCircle Wealth’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,922	Closed	-$356K	–	221
2024 Q3	$356K	Buy	1,922 +16	+0.8%	+$3.35K	0.16%	138
2024 Q2	$431K	Buy	+1,906	New	+$414K	0.21%	122

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

FullCircle Wealth's BIIB Position: Q4 2024 in Review

FullCircle Wealth sold out of Biogen (BIIB) in Q4 2024, closing a stake of 1,922 shares — an estimated $356K sold.

FullCircle Wealth first reported a position in BIIB in Q2 2024 and held it in 2 quarters. The position peaked at $431K in Q2 2024. 876 funds tracked by Wall St. Rank hold BIIB as of Q4 2024.

FullCircle Wealth reported no remaining Biogen position as of Q4 2024 after selling out during the quarter.
FullCircle Wealth sold 1,922 Biogen shares in Q4 2024, an estimated $356K.
FullCircle Wealth first reported a position in Biogen in Q2 2024 and held it in 2 quarters.
FullCircle Wealth's Biogen position peaked at $431K in Q2 2024.
876 funds tracked by Wall St. Rank held Biogen as of Q4 2024.

Based on FullCircle Wealth's 13F filing for Q4 2024, filed 14 Feb 2025.